Hikma Pharmaceuticals Plc Response to unsolicited enquiries (0144Z)
March 01 2013 - 5:24AM
UK Regulatory
TIDMHIK
RNS Number : 0144Z
Hikma Pharmaceuticals Plc
01 March 2013
PRESS RELEASE
Response to unsolicited enquiries
London, 1 March 2013 - Following the receipt of unsolicited
enquiries, Hikma Pharmaceuticals PLC ("Hikma") confirms that it is
undertaking a review of strategic options for its Injectables
business.
Said Darwazah, CEO of Hikma said "We have received a number of
unsolicited expressions of interest in our Injectables business and
will consider the best option for shareholders."
A further announcement will be made if appropriate.
----- ENDS -----
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/
07776 477 050
Lucinda Henderson, Investor Relations Manager +44 (0)20 7399
2765/ 07818 060 211
FTI Consulting +44 (0)20 7831 3113
Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and
in-licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenues of $918.0 million and profit attributable
to shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RSPSSEFSFFDSEED
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024